Related Experiment Video
Updated: Jun 7, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Japan Biotech Forum: London 2010
1Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. asma.al-shamahi@thomsonreuters.com
Abstract:
The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Production of Pharmaceuticals
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Discovery: Overview

